drugset / Trial / NCT06081686
Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This was a multicenter, open-label, phase I/II study to evaluate the safety and tolerability, radiation dosimetry and pharmacokinetic characteristics, and efficacy of \[177Lu\] Lu-XT033 injection in patients with metastatic prostate cancer, including a phase I study and a phase II extension study.
Timeline
- Start
- 2023-09-13
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lu-XT033 | Unknown | 1110 mbq | Intravenous |
| Subject | Lu-XT033 | Unknown | 1850 mbq | Intravenous |